Skip to main content

Advertisement

SpringerLink
Log in

Targeted therapies

Thalidomide in lung cancer therapy—what have we learned?

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

Disappointing phase III results for thalidomide combined with gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer might be related to poor efficacy of targeted therapies in unselected patients. We argue that current trial designs are flawed because they expose large numbers of such patients to potentially harmful treatment, and suggest that future research strategies should prioritize identification of predictive markers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lee, S. M. et al. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer. J. Clin. Oncol. 27, 5248–5254 (2009).

    Article  CAS  PubMed  Google Scholar 

  2. Sandler, A. et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006).

    Article  CAS  PubMed  Google Scholar 

  3. Reck, M. et al. Phase III trial of cisplatin and gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAil. J. Clin. Oncol. 27, 1227–1234 (2009).

    Article  CAS  PubMed  Google Scholar 

  4. Lee, S. M. et al. Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer 59, 346–348 (2008).

    Google Scholar 

  5. Lee, S. M. et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind placebo-controlled trial. J. Natl Cancer Inst. 101, 1049–1057 (2009).

    Article  CAS  PubMed  Google Scholar 

  6. D'Amato, R. J., Loughnans, M. S., Flynn, E. & Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082–4085 (1994).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Franks, M. E., Macphersons, F. G. & Figg, W. D. Thalidomide. Lancet 363, 1802–1811 (2004).

    Article  CAS  PubMed  Google Scholar 

  8. Shaked, Y. et al. Rapid chemotherapy-induced endothelial progenitor cell mobilization: implications for anti-angiogenic drugs as chemosensitizing agents. Cancer Cell 14, 263–273 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Dowlati, A., Gray, R., Sandler, A. B., Schiller, J. H. & Johnson, D. H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab—an Eastern Cooperative Group Study. Clin. Cancer Res. 14, 1407–1412 (2008).

    Article  CAS  PubMed  Google Scholar 

  10. Leighl, N. et al. et al. Analysis of biomarker in the AVAiL phase III randomised study of first-line bevacizumab with cisplatin–gemcitabine in patients with NSCLC [abstract 9172]. Eur. J. Cancer 7 (Suppl.), 558 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, Hamburg, 22927, Germany

    Martin Reck & Ulrich Gatzemeier

Authors
  1. Martin Reck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Gatzemeier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Reck.

Ethics declarations

Competing interests

M. Reck declares that he has acted as a consultant, received honoraria from or is a member of the speakers' bureau for the following companies: Astra-Zeneca, Eli Lilly, Hoffman-La Roche, Merck. U. Gatzemeier declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reck, M., Gatzemeier, U. Thalidomide in lung cancer therapy—what have we learned?. Nat Rev Clin Oncol 7, 134–135 (2010). https://doi.org/10.1038/nrclinonc.2010.11

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.11

  • Springer Nature Limited

Search

Navigation